Conxi Lázaro studied biology in the University of Barcelona. Her PhD thesis was completed in the Genetics Department of the Institut de Recerca Oncològica (IRO) under the supervision of Dr. Estivill. She worked as a Molecular Geneticist at the Genetics Service of Hospital Clínic and after that she returned to IRO to lead the
Neurofibromatosis 1 group as well as to participate in several research projects related to common multifactorial disorders (asthma and psoriasis). During 2003/04 she was a visiting scientist in the Cancer Center of the Massachussetts General Hospital (Harvard, Boston). In 2006 she obtained her current position as a director of the Molecular Diagnostics Unit for Hereditary Cancer at ICO. In addition to the routine clinical work, Dr. Lázaro leads two research lines, one focus on deciphering the genetic basis underlying the Hereditary Breast and Ovarian Cancer Syndrome, and another mainly focus in the development of new therapeutical strategies for
Neurofibroamtosis Type 1. Currently she is also involved in several projects aimed to use Next Generation Sequencing (NGS) for genetic testing purposes. She is a member of the Center of Reference on Neurofibromatosis in Spain and a close collaborator of the different local and international NF Associations.